What is Radialogica?
Radialogica operates at the intersection of medical technology and patient care, providing essential tools that enhance the precision and safety of radiation therapy. The company's platform serves as a critical bridge between clinical practice and research, offering robust quality assurance software that supports both standard treatments and complex clinical trials. With a footprint spanning over 225 clinical sites and impacting more than 1.5 million patient treatments, Radialogica has established itself as a vital partner for pharmaceutical companies, biotech innovators, and medical device manufacturers. Their focus on reducing the burden of cancer survivorship through data-driven insights positions them as a leader in the digital health transformation of oncology departments worldwide.
How much funding has Radialogica raised?
Radialogica has raised a total of $4.7M across 4 funding rounds:
Private Equity
$1.3M
Private Equity
$2.9M
Debt
$150K
Debt
$343K
Private Equity (2013): $1.3M, investors not publicly disclosed
Private Equity (2016): $2.9M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Debt (2021): $343K featuring PPP
Key Investors in Radialogica
PPP
Public-Private Partnership
Undisclosed Private Equity
Institutional investors focused on long-term value creation within the healthcare technology and medical services sectors.
Undisclosed Private Equity
A private equity firm specializing in scaling high-impact healthtech enterprises through significant capital deployment.
What's next for Radialogica?
With the recent influx of capital, Radialogica is well-positioned to accelerate its enterprise-level expansion and deepen its integration within the global oncology ecosystem. The company is expected to leverage this financing to enhance its software suite, potentially incorporating advanced analytics to further refine treatment quality assurance. As the demand for standardized, high-quality radiation therapy grows, Radialogica's strategic roadmap likely includes expanding its footprint in emerging markets and strengthening its collaborative efforts with major medical device manufacturers. This growth trajectory suggests a focus on long-term sustainability and the continued digitization of clinical trial management, ensuring that the firm remains at the forefront of oncology innovation.
See full Radialogica company page
